IL197876A0 - N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression - Google Patents

N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Info

Publication number
IL197876A0
IL197876A0 IL197876A IL19787609A IL197876A0 IL 197876 A0 IL197876 A0 IL 197876A0 IL 197876 A IL197876 A IL 197876A IL 19787609 A IL19787609 A IL 19787609A IL 197876 A0 IL197876 A0 IL 197876A0
Authority
IL
Israel
Prior art keywords
methyl
ylidene
quinolin
thiazol
benzamide
Prior art date
Application number
IL197876A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Ernst Glen
Hudzik Thomas
Bui Khanh
Dantzman Cathy
Hoesch Valerie
King Megan Murphy
Liu Jie
Yan Jingbo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Ernst Glen, Hudzik Thomas, Bui Khanh, Dantzman Cathy, Hoesch Valerie, King Megan Murphy, Liu Jie, Yan Jingbo filed Critical Astrazeneca Ab
Publication of IL197876A0 publication Critical patent/IL197876A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL197876A 2006-10-20 2009-03-26 N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression IL197876A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20
PCT/SE2007/000924 WO2008048171A1 (en) 2006-10-20 2007-10-19 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.

Publications (1)

Publication Number Publication Date
IL197876A0 true IL197876A0 (en) 2009-12-24

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197876A IL197876A0 (en) 2006-10-20 2009-03-26 N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Country Status (32)

Country Link
US (2) US7659286B2 (OSRAM)
EP (1) EP2079735B1 (OSRAM)
JP (1) JP4668346B2 (OSRAM)
KR (1) KR20090065534A (OSRAM)
CN (1) CN101528739B (OSRAM)
AR (1) AR063345A1 (OSRAM)
AT (1) ATE543818T1 (OSRAM)
AU (2) AU2007313515B2 (OSRAM)
BR (1) BRPI0717631A2 (OSRAM)
CA (1) CA2667041C (OSRAM)
CL (1) CL2007003009A1 (OSRAM)
CO (1) CO6180450A2 (OSRAM)
CY (1) CY1112718T1 (OSRAM)
DK (1) DK2079735T3 (OSRAM)
ES (1) ES2379519T3 (OSRAM)
HR (1) HRP20120344T1 (OSRAM)
IL (1) IL197876A0 (OSRAM)
MX (1) MX2009003974A (OSRAM)
MY (1) MY148880A (OSRAM)
NO (1) NO20091969L (OSRAM)
NZ (1) NZ577060A (OSRAM)
PE (2) PE20080892A1 (OSRAM)
PL (1) PL2079735T3 (OSRAM)
PT (1) PT2079735E (OSRAM)
RS (1) RS52260B (OSRAM)
RU (1) RU2454414C2 (OSRAM)
SA (1) SA07280549B1 (OSRAM)
SI (1) SI2079735T1 (OSRAM)
TW (1) TW200826939A (OSRAM)
UA (1) UA97648C2 (OSRAM)
UY (1) UY30652A1 (OSRAM)
WO (1) WO2008048171A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060010811A (ko) * 2003-05-16 2006-02-02 아스트라제네카 아베 디아릴메틸리덴 피페리딘 유도체, 그의 제조 및 그의 용도
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
JP2011520956A (ja) * 2008-05-20 2011-07-21 アストラゼネカ・アクチエボラーグ 不安大うつ病性障害を処置する方法
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
DK3233825T3 (da) * 2014-12-19 2020-06-29 Pharmnovo Ab Diarylmethylidenpiperidinderivater og deres anvendelse som deltaopioidreceptoragonister
US11286728B2 (en) 2018-09-21 2022-03-29 Postle Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
DK1049676T3 (da) * 1997-12-24 2006-01-16 Ortho Mcneil Pharm Inc 4-[Aryl(piperidin-4-yl)]aminobenzamider, som binder til delta-opioidreceptoren
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
EP1242398A2 (en) 1999-12-20 2002-09-25 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6552036B2 (en) 2000-03-03 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
KR20060010811A (ko) 2003-05-16 2006-02-02 아스트라제네카 아베 디아릴메틸리덴 피페리딘 유도체, 그의 제조 및 그의 용도
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
PE20140634A1 (es) 2014-06-19
PL2079735T3 (pl) 2012-07-31
CO6180450A2 (es) 2010-07-19
NZ577060A (en) 2011-01-28
ES2379519T3 (es) 2012-04-26
AR063345A1 (es) 2009-01-21
CN101528739A (zh) 2009-09-09
CA2667041C (en) 2011-09-06
AU2007313515B2 (en) 2010-11-25
AU2010226996A1 (en) 2010-10-28
MX2009003974A (es) 2009-04-27
RS52260B (sr) 2012-10-31
TW200826939A (en) 2008-07-01
EP2079735A1 (en) 2009-07-22
DK2079735T3 (da) 2012-05-21
PE20080892A1 (es) 2008-09-11
WO2008048171A1 (en) 2008-04-24
JP2010506910A (ja) 2010-03-04
US7659286B2 (en) 2010-02-09
HK1131556A1 (en) 2010-01-29
JP4668346B2 (ja) 2011-04-13
HRP20120344T1 (hr) 2012-05-31
UY30652A1 (es) 2008-05-31
US20080182875A1 (en) 2008-07-31
SA07280549B1 (ar) 2010-09-29
MY148880A (en) 2013-06-14
PT2079735E (pt) 2012-05-07
UA97648C2 (ru) 2012-03-12
KR20090065534A (ko) 2009-06-22
CY1112718T1 (el) 2016-02-10
CL2007003009A1 (es) 2008-06-06
CN101528739B (zh) 2011-11-30
EP2079735B1 (en) 2012-02-01
EP2079735A4 (en) 2010-12-29
US7977355B2 (en) 2011-07-12
CA2667041A1 (en) 2008-04-24
ATE543818T1 (de) 2012-02-15
AU2007313515A1 (en) 2008-04-24
US20100160374A1 (en) 2010-06-24
NO20091969L (no) 2009-05-20
RU2009111337A (ru) 2010-11-27
RU2454414C2 (ru) 2012-06-27
SI2079735T1 (sl) 2012-05-31
BRPI0717631A2 (pt) 2013-10-29

Similar Documents

Publication Publication Date Title
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
IL185785A0 (en) Certain substituted amides, method of making, and method of use thereof
HUS1800010I1 (hu) 4-Fenil-6-(2,2,2-trifluor-1-feniletoxi)pirimidin-alapú vegyületek és alkalmazási eljárásaik
ZA200901634B (en) Substituted Amides, method of making, and method of use thereof
ZA200901633B (en) Certain substituted amides, method of making, and method of use thereof
SI2182949T1 (sl) (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciklo(2.2.2)okt-3-il)benzofuran -2-karboksamid, nove oblike soli in postopki za njihovo uporabo
EP1874286A4 (en) METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE
ZA200907137B (en) Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
IL197876A0 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
ZA200706868B (en) 4-Oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
ZA200809565B (en) 4-(2, e-dichloro-benzoylamino)-1H-pyrazole-s-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the treatment of cancer
IL190963A0 (en) Novel processes for the preparation of piperazinly and diazapanyl benzamide derivatives
IL186373A0 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
IL195920A0 (en) 3-(1h-indol-3-ydindan-1-ylamine derivatives for the treatment of depression and anxiety
SG143202A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia
ZA200806876B (en) Crystal form of besipirdine chlorhydrate, process preparation and use thereof
DK1926717T3 (da) Fremgangsmåde til fremstilling af 3,4-dichlor-N-(2-cyano-phenyl)-5-isothiazolcarboxamid
DE602005005343D1 (de) Vorrichtung zur thermomechanischen behandlung bei niedrigem druck
PL375250A1 (pl) Nowe N-[2-(alkoksykarbonylo) etylo]-N-alkilo-1-amino-1-dezoksy-D-glucitole i sposób ich wytwarzania
ZA200708108B (en) Certain substituted amides, method of making, and method of use thereof
ZA200901739B (en) [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
PL377984A1 (pl) Sposób wytwarzania N-(5-amino-2-metylofenylo)-4-(3-pirydylo)-2-pirymidynoaminy
HU0500899D0 (en) Process and device for improvement of herbs